Merck adds to aquaculture portfolio with Vaki purchase
Merck’s (NYSE:MRK) animal health division acquires Vaki, a maker of fish farming and wild fish conservation monitoring equipment, from Pentair (NYSE:PNR) to broaden Merck’s aquaculture portfolio.
Financial terms of the deal weren’t disclosed.
Vaki will be part of the Biomark business within Merck Animal Health, focused on a range of equipment, products, and technology for fish counting and size estimation from freshwater to saltwater rearing, while collecting data and analytics for each stage of fish production.
In March 2019, Merck Animal Health acquired Scan Aqua AS, a Norway-based fish health company focused on key aquaculture products.
CytoDyn out-licenses U.S. rights to leronlimab for HIV for up to $87.5M
CytoDyn (OTCQB:CYDY) inks an agreement with privately held Vyera Pharmaceuticals related to HIV med leronlimab.
Under the terms of the deal, Vyera will have exclusive marketing rights in the U.S. in consideration of upfront and milestone payments up to $87.5M plus a 50% royalty on net sales. It will also invest $4M in CYDY common stock.
CytoDyn will maintain responsibility for development and regulatory filings.
CRH Medical acquires 51% stake in Florida Panhandle Anesthesia Associates
CRH Medical (CRHM -0.3%) acquired a 51% ownership interest in Florida Panhandle Anesthesia Associates, LLC, a gastroenterology anesthesia practice located in Florida.
The transaction was financed through a combination of CRH’s credit facility and cash on hand.
Transaction estimates annual revenue of $2M, and will be EBITDA and cash flow accretive.
BioArctic teams up with Eisai to further characterize Alzheimer’s candidate BAN2401
BioArctic AB (BIOAB:SS) will collaborate with Eisai (OTCPK:ESALY) on research aimed at further characterizing the mechanism of action of Alzheimer’s disease candidate BAN2401, in-licensed by Eisai in December 2007.
Under the terms of the agreement, Eisai will pay up to €3.25M (~SEK 34M) to BioArctic under the partnership, expected to run through June 2021.
Results will be submitted for presentation at future medical conferences.
Eisai is currently conducting a large-scale Phase 3 study, CLARITY AD, with collaboration partner Biogen (BIIB -1.1%) evaluating BAN2401 in patients with early Alzheimer’s. The estimated primary completion date is February 2022.
BAN2401 is a humanized monoclonal antibody that selectively binds to (and eliminates) toxic amyloid beta aggregates in the brain.
Roche finalizes Spark takeover
Roche (OTCQX:RHHBY) has completed its $114.50/share acquisition of Spark Therapeutics (NASDAQ:ONCE).
